Back to results
US 2020/0345773 A1Published application
Engineered phagocytic receptor compositions and methods of use thereof
AssigneeMyeloid Therapeutics, Inc.
InventorsDaniel Getts, Yuxiao Wang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
Claims20
A method of treating cancer in a human subject in need thereof comprising administering a pharmaceutical composition to the human subject, the pharmaceutical composition comprising:
- (a) a myeloid cell comprising a recombinant polynucleic acid sequence, wherein the polynucleic acid sequence comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising:
- (i) an extracellular domain comprising a CD5 binding domain, and (ii) a transmembrane domain operatively linked to the extracellular domain;
- and (b) a pharmaceutically acceptable carrier;
- wherein the myeloid cell expresses the CFP.
1 more element
Dependencies are inferred from the claim text.